These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 35703643)
1. Should we Consider the Stimulation of Soluble Guanylyl Cyclase as Beneficial for Treating Pre-Capillary Pulmonary Hypertension? Alencar AKN Arq Bras Cardiol; 2022 Jun; 118(6):1067-1068. PubMed ID: 35703643 [No Abstract] [Full Text] [Related]
2. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension. Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920 [TBL] [Abstract][Full Text] [Related]
3. Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Oka M; Karoor V; Homma N; Nagaoka T; Sakao E; Golembeski SM; Limbird J; Imamura M; Gebb SA; Fagan KA; McMurtry IF Cardiovasc Res; 2007 Jun; 74(3):377-87. PubMed ID: 17346686 [TBL] [Abstract][Full Text] [Related]
4. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase. Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664 [TBL] [Abstract][Full Text] [Related]
5. Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation. Johns RA; Tichotsky A; Muro M; Spaeth JP; Le Cras TD; Rengasamy A Anesthesiology; 1995 Oct; 83(4):823-34. PubMed ID: 7574063 [TBL] [Abstract][Full Text] [Related]
6. Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats. Reyna-Neyra A; Sarkar G; Etgen AM J Neuroendocrinol; 2007 Jun; 19(6):418-25. PubMed ID: 17388815 [TBL] [Abstract][Full Text] [Related]
7. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Dasgupta A; Bowman L; D'Arsigny CL; Archer SL Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386 [TBL] [Abstract][Full Text] [Related]
8. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
10. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP? Koress C; Swan K; Kadowitz P Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316 [TBL] [Abstract][Full Text] [Related]
11. In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Fedele E; Jin Y; Varnier G; Raiteri M Br J Pharmacol; 1996 Oct; 119(3):590-4. PubMed ID: 8894183 [TBL] [Abstract][Full Text] [Related]
12. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Chester M; Tourneux P; Seedorf G; Grover TR; Gien J; Abman SH Am J Physiol Lung Cell Mol Physiol; 2009 Aug; 297(2):L318-25. PubMed ID: 19465519 [TBL] [Abstract][Full Text] [Related]
13. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs. Thelitz S; Bekker JM; Ovadia B; Stuart RB; Johengen MJ; Black SM; Fineman JR J Thorac Cardiovasc Surg; 2004 May; 127(5):1285-92. PubMed ID: 15115984 [TBL] [Abstract][Full Text] [Related]